Rhelion Life Sciences Corp. RHEL
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -5.03M | -4.42M | -3.55M | -3.17M | -2.74M |
| Total Depreciation and Amortization | 263.30K | 255.70K | 274.20K | 376.10K | 474.70K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.23M | 1.99M | 1.04M | 588.30K | 379.00K |
| Change in Net Operating Assets | 434.90K | 422.90K | 438.40K | 1.41M | 744.90K |
| Cash from Operations | -2.10M | -1.75M | -1.80M | -795.80K | -1.14M |
| Capital Expenditure | -5.80K | -101.30K | -127.00K | -152.20K | -157.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 31.70K | -- | -- | -- | -- |
| Divestitures | 134.20K | -- | -- | -- | -- |
| Other Investing Activities | -4.25M | -785.50K | -712.70K | -483.70K | -147.60K |
| Cash from Investing | -4.09M | -886.80K | -839.60K | -635.90K | -304.80K |
| Total Debt Issued | 24.60K | 4.60K | 204.30K | 27.70K | 27.70K |
| Total Debt Repaid | -139.80K | -770.60K | -695.00K | -733.30K | -767.30K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -85.50K | -555.90K | -357.50K | -511.50K | -536.60K |
| Foreign Exchange rate Adjustments | -129.10K | 34.20K | 78.40K | 96.30K | 44.90K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.40M | -3.16M | -2.92M | -1.85M | -1.94M |